{'fraction_non_alphanumeric': 0.019130434782608695, 'fraction_numerical': 0.010434782608695653, 'mean_word_length': 6.149068322981367, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Resveratrol Inhibition Osteoclastogenesis Induced by RANKL through Decrease Preosteoclast Formation

It has been demonstrated that resveratrol can inhibit osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand (RANKL) in several cell models. However, the mechanism has not yet been completely clarified. In this study, we investigated the effects of resveratrol on osteoclasts differentiation induced by RANKL. Preosteoclast or osteoclast derived from the murine monocytic cell line RAW264.7 treated with RANKL. In RAW264.7 cells culture, data indicated that resveratrol at non-toxic concentrations dose-dependently inhibited the formation of osteoclasts and the activation of tartrate-resistant acid phosphatase (TRAP). Using flow cytometry assay, the results indicated that the percentage of preosteoclast differentiation was decreased by resveratrol, whereas the apoptosis rate of preosteoclasts was not changed. Our results suggest that resveratrol might inhibit the differentiation of RAW264.7 cells into osteoclasts and decrease osteoclast activation possibly via suppressing monocytes to differentiate preosteoclasts.